

## **Connecticut Pub. Act 23-171 Disclosure**

Connecticut law requires pharmaceutical companies to provide healthcare providers with information about the costs of medicines and Information on the variation efficacy of the drug on different racial and ethnic groups. Bristol-Myers Squibb (“BMS”) provides the following information to Connecticut prescribers, in accordance with Conn. Pub. Act 23-171.

The pricing information below reflects BMS’s Wholesale Acquisition Costs (“WAC”) for the BMS product(s) listed below. The WAC represents published catalogue or list price and may not represent actual transactional price.

### **SOTYKTU®** (deucravacitinib)

#### **Legend Drug**

#### **WAC Package Price\***

Sotyktu 6 mg Tablet

\$ 7,135.55 per bottle of 30

#### **Additional Information**

Bristol Myers-Squibb (BMS) does not have data demonstrating variation efficacy for this product in different racial and ethnic groups.

*\*Wholesale Acquisition Cost (WAC) as published by FDB represents the manufacturer’s published catalog or list price for a drug product to wholesalers as reported to FDB by the manufacturer. WAC does not represent actual transaction prices and does not include prompt pay or other discounts, rebates or reductions in price. FDB does not perform any independent investigation or analysis of actual transaction prices for purposes of reporting WAC. FDB relies on manufacturers to report or otherwise make available the values for the WAC.*

*For more information about First Databank’s drug pricing policy, visit  
<https://www.fdbhealth.com/drug-pricing-policy>Source:*

*AnalySource® 01/15/2026 as reprinted with permission by First Databank, Inc. All rights reserved. ©2026*